

The anti-amyloid monoclonal antibody Lecanemab: 16 cautionary notes

Kasper P. Kepp^{*1}, Stefano L. Sensi^{2,3}, Kasper B. Johnsen^{4,5}, Jorge R. Barrio⁶, Poul F. Højlund-Carlsen^{7,8}, Rachael L. Neve⁹, Abass Alavi¹⁰, Karl Herrup¹¹, George Perry¹², Nikolaos K. Robakis¹³, Bryce Vissel^{14,15}, and Alberto J. Espay¹⁶

¹ Department of Chemistry, Section of Biophysical and Biomedical chemistry, Technical University of Denmark, 2800 Kongens Lyngby, Denmark. * E-mail: kpj@kemi.dtu.dk ² Center for Advanced Studies and Technology - CAST, and Institute for Advanced Biotechnology (ITAB), University G. d'Annunzio of Chieti-Pescara, Italy. ³ Department of Neuroscience, Imaging, and Clinical Sciences, University G. d'Annunzio of Chieti-Pescara, Italy. ⁴ Neurobiology Research and Drug Delivery group, Department of Health Science and Technology, Aalborg University, Denmark. ⁵ Section for Research Ethical Evaluation, Danish National Center for Ethics, Denmark. ⁶ Department of Molecular and Medical Pharmacology, UCLA School of Medicine, USA. ⁷ Department of Nuclear Medicine, Odense University Hospital, Odense, Denmark. ⁸ Department of Clinical Research, University of Southern Denmark, Odense, Denmark. ⁹ Department of Neurology, Massachusetts General Hospital, Boston, MA, USA. ¹⁰ Department of Radiology, Hospital of the University of Pennsylvania, Philadelphia, USA. ¹¹ Department of Neurobiology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA. ¹² Department of Neuroscience, Developmental and Regenerative Biology, The University of Texas at San Antonio, San Antonio, Texas, USA. ¹³ Icahn School of Medicine at Mount Sinai, New York, NY, USA. ¹⁴ St Vincent's Hospital Centre for Applied Medical Research, St Vincent's Hospital, Australia. ¹⁵ School of Clinical Medicine, UNSW Medicine & Health, St Vincent's Healthcare Clinical Campus, Faculty of Medicine and Health, UNSW Sydney, Australia. ¹⁶ James J. and Joan A. Gardner Family Center for Parkinson's Disease and Movement Disorders, Department of Neurology, University of Cincinnati, Cincinnati, Ohio, USA.

Abstract

The recent CLARITY AD results for the monoclonal anti-amyloid antibody Lecanemab have been interpreted as promising, supporting the amyloid hypothesis of Alzheimer's disease and leading to consideration for approval by the Food and Drug Administration. Here we explain why the claimed benefits on cognition and activities of daily living are uncertain, why Lecanemab may yield net harm for some subsets of patients and why the data do not prove the amyloid hypothesis but support other important population covariates driving disease. We note potential biases in the cohort arising from inclusion bias, unblinding, and dropouts, among other issues, which may affect the veracity of the data. Together with substantial adverse effects and subgroup heterogeneity, we conclude that Lecanemab's efficacy is not clinically meaningful and may be insignificant when considering the study limitations and biases highlighted. The data are consistent with numerous analyses to date suggesting that A β and its derivatives are not the main causative agents of Alzheimer's dementia.

Keywords: Alzheimer's disease; beta-amyloid; antibody; Lecanemab; subgroup analysis

Introduction

With nearly 40 million Alzheimer's disease (AD) patients in the world and up to a million deaths per year¹⁻³, new treatments are urgently needed^{2,4,5}. Monoclonal amyloid- β peptide (A β) antibodies have received enormous attention as treatments inspired by the amyloid cascade hypothesis⁶⁻⁹. However, many previous antibodies failed in clinical trials and produced adverse effects¹⁰⁻¹³, with Donanemab, Aducanumab, and Lecanemab being possible exceptions by showing some benefits¹⁴⁻¹⁶, although these are modest and highly debated¹⁷⁻²⁰. The Food and Drug Administration (FDA) recently gave accelerated approval of Aducanumab, endorsing drug-induced changes in brain amyloid-levels measured by positron emission tomography (amyloid-PET) as a surrogate measurement of clinical efficacy^{18,21}. This decision caused widespread controversy, with 10 out of 11 independent FDA advisors voting against approval, and three resigning in protest when approval was nevertheless granted against their recommendation^{19,21-26}. More recently, another antibody Lecanemab became the latest in a long list of interventions lowering A β , with FDA approval being sought in early 2023²⁷⁻²⁹.

The amyloid hypothesis

The current definition of AD is predicated on the presence of amyloid deposition of the A β peptide in the brain^{2,30-32}. This disease nosology is based on the amyloid hypothesis stating that an increase in A β aggregation, in one or more *in vivo* molecular forms acting on some processes in the brain, is the primary cause of disease^{6,7,9} and thus that therapies that reduce A β should have a strong beneficial impact¹³. However, dementia associated with AD is a complex disorder^{5,33-43}, with genome-wide association studies implicating risk genes unrelated to A β processing⁴⁴⁻⁴⁸, as well as diverse metabolic^{49,50}, vascular⁵¹⁻⁵³ and other important risk factors^{1,38,54}. Furthermore, familial AD (fAD) which results in genetically determined increase in A β deposition in the brain, represents only a very small percentage of total cases with the large majority occurring sporadically^{55,56}. It is not yet clear that A β is the cause of dementia in fAD, or that fAD and sporadic AD (sAD) are the same disease, and that A β is a major risk factor for sAD, as amyloid load correlates only modestly with clinical presentation⁵⁷⁻⁶⁰ (see also below). Many people have brain A β amyloid fulfilling diagnostic criteria for AD yet without symptoms^{57,61-65},

and technical challenges limit the use of amyloid-PET as a surrogate^{63,66–69}, with the amyloid-PET-clinical relationship being uncertain and sometimes possibly based on misinterpreted data⁷⁰.

Lecanemab

The monoclonal antibody Lecanemab was designed to target the N-terminal region of A β protofibrils deriving from the Arctic APP mutant, which favors protofibril formation²⁸. The new data for Lecanemab from the phase 3 Clarity AD trial showed a modest but statistically significant clinical effect of slowing cognitive decline during the 18-month study period in a subset of patients²⁹. The primary endpoint was the change in score on the 18-point Clinical Dementia Rating–Sum of Boxes (CDR-SB), but there were also significant effects on secondary endpoints, such as –1.44 on the 90-point Alzheimer’s Disease Assessment Scale (ADAS-Cog14)²⁹. For the primary endpoint, the mean change vs. the baseline (3.2) was approximately –0.45 difference vs. placebo (1.21 with Lecanemab and 1.66 with placebo), whereas for ADAS-Cog14 the effect was –1.44. This is claimed as a 27% reduced cognitive decline vs. placebo²⁹. It was also claimed, based on an interpretation of the primary endpoint curve, that Lecanemab slows disease progression relative to placebo by about half a year²⁹. These effects were associated with a clear reduction of amyloid-PET signal, as designed, but also with increased levels of CSF A β ₄₂. However, upon analyzing these data, we propose that there are many uncertainties that should be considered in relation to Lecanemab.

Cautionary notes regarding Lecanemab’s efficacy

Several points regarding both the efficiency and risk-benefit balance are noteworthy:

(1) Lecanemab use was associated with a 27% slowing of decline in the CDR-SB measure of cognition, relative to the placebo group. However, the absolute reduction relative to placebo is 0.45 on an 18-point scale. The authors stated that “A definition of clinically meaningful effects in the primary end point of the CDR-SB score has not been established” but recent literature estimates this to be equal to 1^{71,72}. That is, an effect below 1 cannot be expected to be perceived by patients. Furthermore, the 0.45 points reduction in decline seen in the Lecanemab group is a maximal effect achieved after careful patient selection (59.6% of initially screened individuals at many sites did not meet inclusion criteria or fulfilled exclusion criteria) and may be subject to

uncertainties and potential biases (see below). The problem will be compounded in real life use, where many patients have numerous co-morbidities, plausibly reducing further the impact of the drug. It is also unknown whether the “maximal benefits” seen in this trial will persist over longer exposure, or after drug is ceased, even in this highly selected cohort²⁹.

(2) Bias from unblinding of patients due to protocols related to ARIA and infusion reactions could reduce the effect further⁷³. Although the authors performed sensitivity analysis to address this²⁹, a quarter of the treatment arm had such effects and the risk of functional unblinding from ARIA cannot be overcome by blinded raters when patients learned they are on treatment by virtue of side effects. Such unblinding biases responses on subjective scales such as CDR-SB, ADCOMS & ADCS-ADL-MCI.

(3) The endpoint measurements are based on a reduced cohort due to faster dropout in the treatment group. Although relatively small as judged from the total dropout rates (many of which are non-problematic) there were more than double the dropout rates in the treatment group due to severe adverse events (6.9% vs. 2.9%), and the analysis was done with the reduced cohort, not the final cohort at 18 months. Thus, the particularly worse outcomes in the treatment group continuously dropped out at more than double the rate of the placebo group. For the survival analysis in Figure S6 of the paper²⁹ (“time to worsening of global CDR score”, rate of progression to “next stage”) the dropout was very large. Such drop out differences are a well-known source of bias⁷⁴ and could explain some of the difference between the primary and secondary endpoints. It is unclear whether this large dropout rate influenced the data. Thus, the trial data need to be analyzed with standard methods to at least show how large an impact this bias has on the endpoint curves⁷⁵.

(4) The effect was extremely heterogenous in the subgroup analysis. For example, all endpoints showed 100–300% more effect in men. For the primary endpoint the effect in women was only 12%, vs. 43% for men, an enormous 3.5-fold difference in impact (Figure S1B). This needs to be understood either biologically, as an artefact relating to the biases discussed above, or at least, as a point of note for the label regarding the lesser effect and therefore lower benefit-risk ratio in women (who are more at risk of AD) if eventually approved.

(5) The *APOE* ϵ 4 genotype was associated with a consistent reduction of the clinical benefit of Lecanemab (non-carriers most benefit, heterozygotes less benefit, and homozygotes even less

benefit). *APOE* $\epsilon 4$ is a known risk factor for AD and has been thought to enhance A β pathology^{38,76,77}. Quite apart from clinical implications, the fact that people at higher AD risk due to *APOE* $\epsilon 4$ showed less benefit with Lecanemab is hard to reconcile with the amyloid-based disease hypothesis (i.e., if patients are at increased risk, they should have responded better to a treatment targeting the primary cause). Together with the influence of population covariates on outcome in the subgroups, the result in practice suggests involvement of important *non-amyloid* etiologies.

(6) Europeans had only 41% of the benefit of the drug measured on the primary endpoint compared to Americans ((CDR-SB; 14 vs. 34%, Figure S1A). Given the very large confidence intervals, some of this could be real population covariates or mostly low sampling certainty, invoking the need for further data. This is particularly true since in the current trial data, population health covariates influence the claimed efficiency by the same magnitude as the effects observed, which suggests that the trial may have identified previously unidentified covariates of AD risk and progression.

(7) The subgroup analysis for the ADAS-Cog14 score also shows a concerning tendency that the use of symptomatic medicine at baseline dominates as a covariate of the endpoint efficacy, with almost double efficacy of Lecanemab if the patient is already on a symptomatic medicine (Figure S2 of the paper²⁹). This is not expected from a causal disease-modifying treatment.

(8) Further supporting this concern are previous trials giving remarkably similar effect curve shapes for non-causal (symptomatic) drugs such as donepezil^{78,79}. If Lecanemab had been disease modifying one would expect a larger effect. Furthermore, the similarity for the two drugs suggests that Lecanemab does not work by disease modification but by some other non-specific effect or a common bias in the trial, such as drop-out, unblinding or cohort selection bias discussed above.

(9) For both the primary endpoint CDR-SB and for ADAS-Cog14, age was a major covariate of efficacy, with the drug having essentially no effect on the primary endpoint for patients < 65 years (6% vs. 23–40% in the higher ages, large confidence interval, Figure S1B) and half effect by ADAS-Cog (14% vs. 29–30% for older ages, Figure S2B). Notably this 6% CDR-SB effect for combined sex <65 years includes women with less than 1/3 benefit as judged from the sex-stratified estimate for all ages (12% women, 43% men, Figure S1B in the paper²⁹).

(10) The combined subgroup results suggest that effects could in fact be negative in some patient groups, such as *APOE* ϵ 4 allele carriers, Europeans below 65 years, women, and especially combinations of these. These effects probably reflect demographic risk factors and show the importance of other covariates determining disease outcome than A β amyloid alone. However, subgroup stratification of adverse effects as well as clinical effects of composite groups are missing for those in whom administration could plausibly be net harmful (e.g., female *APOE* ϵ 4 carriers under 65y).

Points of caution regarding adverse effects as red flags

(11) One of the advantages of Lecanemab is its development based on the Arctic APP mutation (E22G) that presumably forms protofibrils quickly, making the antibody attack N-terminal epitopes of protofibrils²⁸ and supposedly producing fewer amyloid-related imaging abnormalities (ARIA), the most prevailing adverse effect seen for these types of antibodies²⁷. Yet, the adverse effects in Table 3 of the trial paper were very substantial and included 12.6% ARIA²⁹.

(12) The twice as high drop-out rate in the treatment group due to serious adverse effects (6.9 vs. 2.9%)²⁹ not only risks biasing the efficacy estimates in the endpoint curves, but is also by itself a red flag on overall risk-benefit: An overall good drug in balance of benefits and adverse effects would not be expected to give so many more adverse effects in the treatment group. Long-term follow up of all patients, including those who left the trial, is essential before drawing conclusions about the safety of the drug.

(13) Another separate major concern is the evidence for brain atrophy in both the Phases 2 and 3 of Lecanemab²⁷. Brain volume changes are also seen with other antibodies⁸⁰. Just as amyloid accumulation does not cause brain swelling, amyloid clearance is not very likely to explain the brain atrophy, as postmortem studies in preclinical models and patients indicate that the overall volume of amyloid deposition accounts for less than 1% of the neocortex^{81,82}, i.e., this could be a red flag of neuronal damage. The lack of rigorous data ruling out brain volume changes due to treatment related tissue damage is of utmost concern for clinicians and patients.

(14) Another important red flag is the reports of three deaths during the trial, several associated with ARIA⁸³⁻⁸⁵, although anticoagulants may have contributed to the observed brain swelling and haemorrhage.^{83,84} The trial authors stated that there were no deaths associated with

ARIA²⁹. However, independent assessments suggest Lecanemab contributed to death in at least two subsequent cases^{84,85}, which urgently requires analysis before FDA moves to approval, as fatal outcomes due to ARIA (with a prevalence of 12.6%) could change the risk-benefit balance considerably, especially given lack of long-term follow-up information.

(15) That ARIA increases with *APOE* ϵ 4 genotype, as also seen for Gantenerumab⁸⁶ and Bapineuzumab¹², strongly argues for caution of use in these patients⁸⁷ and illustrates the importance of having both adverse effects and clinical benefits stratified better on population subgroups, in order to first do no harm.

(16) Importantly, especially in context with the above-described heterogeneity and uncertainty, the trial was short, and we do not know the long-term effects of treatment; it is possible that there is an unexpected long-term impact (e.g., of ARIA) that change the risk-benefit substantially. In addition to the many concerns, we must prepare for the eventuality that the real-world effects of Lecanemab may be much smaller than reported in the trial, due to the biases and heterogeneity discussed above. We note that patients often have comorbidities that make them more vulnerable to side effect risks and less likely to respond to treatment.

In sum, the data point to limited if any benefit on cognition and potential net detrimental effects at very least for particular patient subgroups (e.g., women, Europeans, people under 65, and *APOE* ϵ 4 carriers). Taken as a whole, the data do not provide compelling evidence for benefits of Lecanemab on cognition, while the risks remain poorly understood.

Discussion: CLARITY AD in context

There was strong evidence before Lecanemab of a limited impact of reducing $A\beta$ in AD patients¹³. The amyloid hypothesis, the theoretical basis for the $A\beta$ reduction strategy, has been criticized for its simplicity and inconsistencies^{31,33,88–96}. Many fAD mutations associate with reduced $A\beta$ production^{31,97–105} but increase the $A\beta_{42}/A\beta_{40}$ ratio^{106–108}. $A\beta$ toxicity conclusions were drawn from $A\beta$ applied to cells at 1000-fold physiological $A\beta$ concentrations^{33,97}. The absence of fAD mutations in the α - and β -secretase that prevent or start production of $A\beta$ ¹⁰⁹ or in non-PS1 subunits of γ -secretase important for enzyme^{110,111} production of $A\beta$ also suggests against $A\beta$ processing as a major single cause of AD. Along similar lines, no known mutations yield fAD risk in the key metalloproteases degrading $A\beta$, such as insulin degrading enzyme^{112–114} and

neprilysin^{115–117}, expected if A β overload really caused disease⁹⁶. Such anomalies among many others^{31,33,91,96,97,109,118,119} illustrate that lowering of A β by itself cannot have a major impact.

These expectations have been confirmed in clinical trials, including now Lecanemab: We disagree that disease modification was demonstrated, since biomarker changes were not correlated directly to same subgroup clinical outcomes or studied for causal relationships. There was no evidence of dose-response effect as this was a single-dose trial. ARIA is known to be dose-dependent from previous antibody trials¹²⁰, and we expect at least the same level of dose-response benefit as adverse effects if a drug is disease-modifying.

The claimed beneficial effects with Lecanemab in some subgroups (but not clearly in all, see above)²⁹, if indeed they were to hold up, are not understood and could be due to clearance of toxic A β , precursors of this A β , or reconstitution of beneficial A β monomers¹²¹. While the association between brain amyloid and cognitive impairment is poor, reaching 5:1 ratio by age 85^{122,123}, the correlation between low soluble A β ₄₂ and dementia is high: Most individuals with AD have CSF A β ₄₂ below 800 pg/ml¹²⁴. Soluble A β ₄₂ increased substantially due to Lecanemab treatment (Figure S5 in²⁹), which has been associated with a net positive clinical effect by itself^{124,125}.

We also note that the Clarity AD trial confirms previous data in suggesting that A β by itself is not a major cause of AD⁹⁷. Lecanemab offers yet further evidence that anti-amyloid therapies are unlikely to produce clinically meaningful benefits in broader patient groups.

Real-world clinical use of Lecanemab

It could be claimed that a modest decline of cognition in a relatively healthy patient cohort over the 18 months of the CLARITY AD trial would make positive effects harder to identify, such that even minimal effect seen on cognition should be a cause of optimism. However, uncertainty of effect is not an argument for treatment with so many red flags. The 59.6% non-inclusion suggests that the cohort is far from representative of real-world settings, where desperate patients and busy clinicians meet. Under the pressures of intense clinical practice with broader patient groups, the drug is unlikely to work as well as in the ideal settings monitored by Clarity AD *even* if biases and subgroup heterogeneity discussed above had been small. In other words, the uncertainty of benefit is very much to the direction of smaller, if any, effect.

While it is thus unclear whether the short 18-month trial documents meaningful benefits, the long-term risks are also unclear. We have pointed above to our concerns about the high drop-out rate, red flags relating to mortality, and uncertain long-term adverse effects, including but not limited to AD patients with comorbidities excluded from the trial, and concerns about brain-volume loss that have been inadequately addressed, among other issues. Stringent monitoring of side effects will be much more difficult in real-world settings where many comorbidities are the rule, not the exception. Accordingly, the long-term risk-benefit balance of the drug is very unclear, with some patient groups (e.g., women under 65y or *APOE* ϵ 4 carriers) potentially at even greater risk of net harm from administration. The data in the study are insufficient to allow us to estimate this issue, which again suggests against therapeutic use to patient groups in real-world settings without a much better understanding of the risk-benefit balance.

Finally, the issue of financial sustainability should be addressed, as these costly and marginally effective therapies may deplete funding on public and private health budgets.

Conclusions

Analysis of the available data from CLARITY-AD suggests that Lecanemab's efficacy is below that accepted as clinically meaningful. There are potential biases in the cohort from inclusion bias, unblinding, and dropouts, among other issues, which may affect the veracity of the data. Substantial adverse effects and subgroup heterogeneity is clearly present. Thus, the translation of the clinical trial data into real world effects is very uncertain. All these issues are consistent with a large body of previous data suggesting that A β overall plays a minor role in etiology despite its clear role in pathology.

The present discussion is urgent for everyone – patients and clinicians, but also researchers. There is reason for concern based on an objective assessment of the available data. To end the scourge of AD on our families and our society, we must ensure scientific and medical rigor focused on developing other etiology-based treatments for this devastating disease.

Conflicts of interest

Dr. Sensi has received grant support from the Alzheimer's Association, The Italian Ministry of Health and the Italian Ministry of Research. He is a scientific advisory board member without compensation for SINDEM the Italian Neurological Society for the Study of Dementia. He serves on the editorial boards of the Journal of Alzheimer's Disease, PLOS ONE, Frontiers in Aging, Frontiers in Neuroscience, and Frontiers in Psychiatry.

Dr. Perry is a consultant for Synaptogenix and Nervgen and is acting Editor-in-Chief of the Journal of Alzheimer's Disease.

Dr. Espay has received consultant fees from Neuroderm, Amneal, Acadia, Acorda, Bexion, Kyowa Kirin, Sunovion, Supernus (formerly, USWorldMeds), Avion Pharmaceuticals, and Herantis Pharma; honoraria for speakership for Avion; and publishing royalties from Lippincott Williams & Wilkins, Cambridge University Press, and Springer. He cofounded REGAIN Therapeutics and is co-owner of a patent on synthetic soluble nonaggregating peptide analogues. He serves on the editorial boards of the Journal of Parkinson's Disease, Journal of Alzheimer's Disease, European Journal of Neurology, Movement Disorders Clinical Practice, and JAMA Neurology.

Other authors did not report any conflicts of interest related to this work.

References

1. Nichols, E. *et al.* Global, regional, and national burden of Alzheimer's disease and other dementias, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet Neurol.* **18**, 88–106 (2019).
2. Blennow, K., de Leon, M. J. & Zetterberg, H. Alzheimer's disease. *Lancet* **368**, 387–403 (2015).
3. Prince, M., Comas-Herrera, A., Knapp, M., Guerchet, M. & Karagiannidou, M. World Alzheimer Report 2016 Improving healthcare for people living with dementia. Coverage, Quality and costs now and in the future. *Alzheimer's Dis. Int.* 1–140 (2016).
4. Bäckman, K. *et al.* 37 Years of Body Mass Index and Dementia: Effect Modification by the APOE Genotype: Observations from the Prospective Population Study of Women in Gothenburg, Sweden. *J. Alzheimer's Dis. J. Alzheimers Dis, J. Alzheimers Dis. J Alzheimers Dis, J Alzheimer's Dis* **48**, (2015).
5. Karran, E. & Hardy, J. A critique of the drug discovery and phase 3 clinical programs targeting the amyloid hypothesis for Alzheimer disease. *Ann. Neurol.* **76**, 185–205 (2014).
6. Wong, C. W., Quaranta, V. & Glenner, G. G. Neuritic plaques and cerebrovascular amyloid in Alzheimer disease are antigenically related. *Proc. Natl. Acad. Sci.* **82**, 8729–8732 (1985).
7. Glenner, G. G. & Wong, C. Amyloidosis in Alzheimer's disease and Down's Syndrome. in *Molecular Neuropathology of Aging* (eds. Davies, P. & Finch, C. E.) 253–265 (Cold Spring Harbor Laboratory Press, 1987).
8. Hardy, J. Alzheimer's disease: The amyloid cascade hypothesis - An update and reappraisal. *J. Alzheimer's Dis.* **9**, 151–153 (2006).
9. Masters, C. L. *et al.* Amyloid plaque core protein in Alzheimer disease and Down syndrome. *Proc. Natl. Acad. Sci.* **82**, 4245–4249 (1985).
10. Honig, L. S. *et al.* Trial of solanezumab for mild dementia due to Alzheimer's disease. *N. Engl. J. Med.* **378**, 321–330 (2018).
11. Doody, R. S. *et al.* Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. *N. Engl. J. Med.* **370**, 311–321 (2014).

12. Salloway, S. *et al.* Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease. *N. Engl. J. Med.* **370**, 322–333 (2014).
13. Richard, E., den Brok, M. G. H. E. & van Gool, W. A. Bayes analysis supports null hypothesis of anti-amyloid beta therapy in Alzheimer's disease. *Alzheimer's Dement.* **17**, 1051–1055 (2021).
14. Mintun, M. A. *et al.* Donanemab in Early Alzheimer's Disease. *N. Engl. J. Med.* **384**, 1691–1704 (2021).
15. Howard, R. & Liu, K. Y. Questions EMERGE as Biogen claims aducanumab turnaround. *Nat. Rev. Neurol.* **16**, 63–64 (2020).
16. Mahase, E. Lecanemab trial finds slight slowing of cognitive decline, but clinical benefits are uncertain. *BMJ* **379**, o2912 (2022).
17. Espay, A. J. Donanemab in Early Alzheimer's Disease. *The New England journal of medicine* **385**, 666–667 (2021).
18. Knopman, D. S., Jones, D. T. & Greicius, M. D. Failure to demonstrate efficacy of aducanumab: An analysis of the EMERGE and ENGAGE trials as reported by Biogen, December 2019. *Alzheimer's Dement.* **17**, 696–701 (2021).
19. Alexander, G. C., Emerson, S. & Kesselheim, A. S. Evaluation of Aducanumab for Alzheimer Disease: Scientific Evidence and Regulatory Review Involving Efficacy, Safety, and Futility. *JAMA* **325**, 1717–1718 (2021).
20. The Lancet. Lecanemab for Alzheimer's disease: tempering hype and hope. *Lancet* **400**, 1899 (2022).
21. Alexander, G. C. *et al.* Revisiting FDA approval of aducanumab. *N. Engl. J. Med.* **385**, 769–771 (2021).
22. Schneider, L. S. Aducanumab Trials EMERGE But Don't ENGAGE. *The Journal of Prevention of Alzheimer's Disease* 1–4 (2022).
23. Musiek, E. S., Gomez-Isla, T. & Holtzman, D. M. Aducanumab for Alzheimer disease: the amyloid hypothesis moves from bench to bedside. *J. Clin. Invest.* **131**, e154889 (2021).
24. Lundebjerg, N. E., Hollmann, P. A. & Supiano, M. A. Of education and public policy: Aducanumab. *J. Am. Geriatr. Soc.* **70**, 81–84 (2022).
25. Tagliavini, F., Tiraboschi, P. & Federico, A. Alzheimer's disease: The controversial

- approval of Aducanumab. *Neurological Sciences* **42**, 3069–3070 (2021).
26. Costa, T. & Cauda, F. A bayesian reanalysis of the phase III aducanumab (ADU) trial. *J. Alzheimer's Dis.* 1–4 (2021).
 27. Swanson, C. J. *et al.* A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-A β protofibril antibody. *Alzheimers. Res. Ther.* **13**, 1–14 (2021).
 28. Söderberg, L. *et al.* Lecanemab, Aducanumab, and Gantenerumab — Binding Profiles to Different Forms of Amyloid-Beta Might Explain Efficacy and Side Effects in Clinical Trials for Alzheimer's Disease. *Neurotherapeutics* in press (2022). doi:10.1007/s13311-022-01308-6
 29. van Dyck, C. H. *et al.* Lecanemab in Early Alzheimer's Disease. *N. Engl. J. Med.* **published**, (2022).
 30. Johnson, K. A. *et al.* Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association. *J. Nucl. Med.* **54**, 476–490 (2013).
 31. Morris, G. P., Clark, I. A. & Vissel, B. Inconsistencies and controversies surrounding the amyloid hypothesis of Alzheimer's disease. *Acta Neuropathol. Commun.* **2**, 135 (2014).
 32. Morris, G. P., Clark, I. A. & Vissel, B. Questions concerning the role of amyloid- β in the definition, aetiology and diagnosis of Alzheimer's disease. *Acta Neuropathol.* **136**, 663–689 (2018).
 33. Neve, R. L. & Robakis, N. K. Alzheimer's disease: a re-examination of the amyloid hypothesis. *Trends Neurosci.* **21**, 15–19 (1998).
 34. Kepp, K. P. Alzheimer's disease due to loss of function: A new synthesis of the available data. *Prog. Neurobiol.* **143**, 36–60 (2016).
 35. Extance, A. Alzheimer's failure raises questions about disease-modifying strategies. *Nat. Rev. Drug Discov.* **9**, 749–751 (2010).
 36. Karantzoulis, S. & Galvin, J. E. Distinguishing Alzheimer's disease from other major forms of dementia. *Expert Rev. Neurother.* **11**, 1579–1591 (2011).
 37. Holmes, C. Genotype and phenotype in Alzheimer's disease. *Br. J. Psychiatry* **180**, 131–134 (2002).

38. Tanzi, R. E. The genetics of Alzheimer disease. *Cold Spring Harb. Perspect. Med.* **2**, a006296- (2012).
39. Carreiras, M., Mendes, E., Perry, M., Francisco, A. & Marco-Contelles, J. The Multifactorial Nature of Alzheimer's Disease for Developing Potential Therapeutics. *Curr. Top. Med. Chem.* **13**, 1745–1770 (2013).
40. Heneka, M. T. *et al.* Neuroinflammation in Alzheimer's disease. *Lancet Neurol.* **14**, 388–405 (2015).
41. Beydoun, M. A. *et al.* Epidemiologic studies of modifiable factors associated with cognition and dementia: systematic review and meta-analysis. *BMC Public Health* **14**, 643 (2014).
42. Mayeux, R. Epidemiology of neurodegeneration. *Annu. Rev. Neurosci.* **26**, 81–104 (2003).
43. Guo, T. *et al.* Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer's disease. *Mol. Neurodegener.* **15**, 40 (2020).
44. Medway, C. & Morgan, K. Review: The genetics of Alzheimer's disease; putting flesh on the bones. *Neuropathol Appl Neurobiol* **40**, 97–105 (2014).
45. Bertram, L. & Tanzi, R. E. Genome-wide association studies in Alzheimer's disease. *Hum. Mol. Genet.* **18**, R137–R145 (2009).
46. Hollingworth, P., Harold, D., Jones, L., Owen, M. J. & Williams, J. Alzheimer's disease genetics: Current knowledge and future challenges. *Int. J. Geriatr. Psychiatry* **26**, 793–802 (2011).
47. Harold, D. *et al.* Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. *Nat. Genet.* **41**, 1088–1093 (2009).
48. Karch, C. M. & Goate, A. M. Alzheimer's disease risk genes and mechanisms of disease pathogenesis. *Biol. Psychiatry* **77**, 43–51 (2015).
49. Virta, J. J. *et al.* Midlife cardiovascular risk factors and late cognitive impairment. *Eur. J. Epidemiol.* **28**, 405–416 (2013).
50. Diaz, R. Obesity: Overweight as a risk factor for dementia. *Nat. Rev. Endocrinol.* **5**, (2009).
51. Love, S. & Miners, J. S. Cerebrovascular disease in ageing and Alzheimer's disease. *Acta Neuropathol.* **131**, 645–658 (2016).
52. Ronnema, E., Zethelius, B., Lannfelt, L. & Kilander, L. Vascular Risk Factors and

- Dementia: 40-Year Follow-Up of a Population-Based Cohort. *Dement. Geriatr. Cogn. Disord. Dement. Geriatr. Cogn. Disord, Dement G C, Dement Geriatr Cogn, Dement Geriatr Cogn Disord, Dement. Geriatr Cogn Disord* **31**, 460–466 (2011).
53. Sweeney, M. D. *et al.* Vascular dysfunction-The disregarded partner of Alzheimer's disease. *Alzheimers. Dement.* **15**, 158–167 (2019).
 54. Kunkle, B. W. *et al.* Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates Abeta, tau, immunity and lipid processing. *Nat. Genet.* **51**, 414–430 (2019).
 55. Van Cauwenberghe, C., Van Broeckhoven, C. & Sleegers, K. The genetic landscape of Alzheimer disease: Clinical implications and perspectives. *Genet. Med.* **18**, 421–430 (2016).
 56. Tang, N., Dehury, B. & Kepp, K. P. Computing the Pathogenicity of Alzheimer's Disease Presenilin 1 Mutations. *J. Chem. Inf. Model.* **59**, 858–870 (2019).
 57. Giannakopoulos, P. *et al.* Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer's disease. *Neurology* **60**, 1495–1500 (2003).
 58. Villemagne, V. L. *et al.* Longitudinal assessment of A β and cognition in aging and Alzheimer disease. *Ann. Neurol.* **69**, 181–192 (2011).
 59. Bush, A. I. & Tanzi, R. E. Therapeutics for Alzheimer's disease based on the metal hypothesis. *Neurotherapeutics* **5**, 421–432 (2008).
 60. Jung, Y. *et al.* Regional β -amyloid burden does not correlate with cognitive or language deficits in Alzheimer's disease presenting as aphasia. *Eur. J. Neurol.* **23**, 313–319 (2016).
 61. Aizenstein, H. J. *et al.* Frequent amyloid deposition without significant cognitive impairment among the elderly. *Arch. Neurol.* **65**, 1509–1517 (2008).
 62. Bennett, D. A. *et al.* Neuropathology of older persons without cognitive impairment from two community-based studies. *Neurology* **66**, 1837–1844 (2006).
 63. Høilund-Carlsen, P. F., Barrio, J. R., Gjedde, A., Werner, T. J. & Alavi, A. Circular inference in dementia diagnostics. *J. Alzheimer's Dis.* **63**, 69–73 (2018).
 64. Bouwman, F. H. *et al.* CSF biomarker levels in early and late onset Alzheimer's disease. *Neurobiol. Aging* **30**, 1895–1901 (2009).
 65. Price, J. L. *et al.* Neuropathology of nondemented aging: presumptive evidence for

- preclinical Alzheimer disease. *Neurobiol. Aging* **30**, 1026–1036 (2009).
66. Høilund-Carlsen, P. F. & Alavi, A. Aducanumab (marketed as aduhelm) approval is likely based on misinterpretation of PET imaging data. *J. Alzheimer's Dis.* **84**, 1457–1460 (2021).
 67. Kepe, V. *et al.* Amyloid- β positron emission tomography imaging probes: a critical review. *J. Alzheimer's Dis.* **36**, 613–631 (2013).
 68. McKhann, G. M. *et al.* The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimer's Dement.* **7**, 263–269 (2011).
 69. Alavi, A. *et al.* Suboptimal validity of amyloid imaging-based diagnosis and management of Alzheimer's disease: why it is time to abandon the approach. *European Journal of Nuclear Medicine and Molecular Imaging* **47**, 225–230 (2020).
 70. Høilund-Carlsen, P. F., Revheim, M.-E., Alavi, A., Satyamurthy, N. & Barrio, J. R. Amyloid PET: A Questionable Single Primary Surrogate Efficacy Measure on Alzheimer Immunotherapy Trials. *J. Alzheimer's Dis.* **90**, 1395–1399 (2022).
 71. Lansdall, C. J. *et al.* Establishing Clinically Meaningful Change on Outcome Assessments Frequently Used in Trials of Mild Cognitive Impairment Due to Alzheimer's Disease. *J. Prev. Alzheimer's Dis.* (2022). doi:10.14283/jpad.2022.102
 72. Andrews, J. S. *et al.* Disease severity and minimal clinically important differences in clinical outcome assessments for Alzheimer's disease clinical trials. *Alzheimer's & Dement. Transl. Res. & Clin. Interv.* **5**, 354–363 (2019).
 73. Gleason, A., Ayton, S. & Bush, A. I. Unblinded by the light: ARIA in Alzheimer's clinical trials. *Eur. J. Neurol* **28**, e1 (2021).
 74. Bell, M. L., Kenward, M. G., Fairclough, D. L. & Horton, N. J. Differential dropout and bias in randomised controlled trials: when it matters and when it may not. *BMJ* **346**, e8668 (2013).
 75. Lane, P. Handling drop-out in longitudinal clinical trials: a comparison of the LOCF and MMRM approaches. *Pharm. Stat. J. Appl. Stat. Pharm. Ind.* **7**, 93–106 (2008).
 76. Pastor, P. *et al.* Apolipoprotein E ϵ 4 modifies Alzheimer's disease onset in an E280A PS1

- kindred. *Ann. Neurol.* **54**, 163–169 (2003).
77. Liu, C.-C. *et al.* ApoE4 accelerates early seeding of amyloid pathology. *Neuron* **96**, 1024–1032 (2017).
 78. Rogers, S. L., Doody, R. S., Mohs, R. C., Friedhoff, L. T. & Group, D. S. Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. *Arch. Intern. Med.* **158**, 1021–1031 (1998).
 79. Seltzer, B. *et al.* Efficacy of donepezil in early-stage Alzheimer disease: a randomized placebo-controlled trial. *Arch. Neurol.* **61**, 1852–1856 (2004).
 80. Novak, G. *et al.* Changes in Brain Volume with Bapineuzumab in Mild to Moderate Alzheimer’s Disease. *J. Alzheimer’s Dis.* **49**, 1123–1134 (2016).
 81. Madsen, J. B., Folke, J. & Pakkenberg, B. Stereological Quantification of Plaques and Tangles in Neocortex from Alzheimer’s Disease Patients. *J. Alzheimer’s Dis.* **64**, 723–734 (2018).
 82. Reilly, J. F. *et al.* Amyloid deposition in the hippocampus and entorhinal cortex: Quantitative analysis of a transgenic mouse model. *Proc. Natl. Acad. Sci.* **100**, 4837–4842 (2003).
 83. Christensen, J. Experimental Alzheimer’s drug may have contributed to death of study participant, according to reports. *CNN* (2022).
 84. Piller, C. Second death linked to potential antibody treatment for Alzheimer’s disease. *Science* (2022).
 85. Charles Piller. Scientists tie third clinical trial death to experimental Alzheimer’s drug. *Science* (2022).
 86. Ostrowitzki, S. *et al.* A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease. *Alzheimers. Res. Ther.* **9**, 1–15 (2017).
 87. Sperling, R. *et al.* Amyloid-related imaging abnormalities in patients with Alzheimer’s disease treated with bapineuzumab: a retrospective analysis. *Lancet Neurol.* **11**, 241–249 (2012).
 88. Ricciarelli, R. & Fedele, E. The Amyloid Cascade Hypothesis in Alzheimer’s Disease: It’s Time to Change Our Mind. *Curr. Neuropharmacol.* **15**, 926–935 (2017).
 89. Smith, M. A., Joseph, J. A. & Perry, G. Arson. Tracking the culprit in Alzheimer’s disease.

- Ann. N. Y. Acad. Sci.* **924**, 35–38 (2000).
90. Smith, M. A., Casadesus, G., Joseph, J. A. & Perry, G. Amyloid- β and τ serve antioxidant functions in the aging and Alzheimer brain. *Free Radic. Biol. Med.* **33**, 1194–1199 (2002).
 91. Lee, H. *et al.* Challenging the amyloid cascade hypothesis: Senile plaques and amyloid- β as protective adaptations to Alzheimer disease. *Ann. N. Y. Acad. Sci.* **1019**, 1–4 (2004).
 92. Rogaeva, E. *et al.* The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease. *Nat. Genet.* **39**, 168–177 (2007).
 93. Barnard, N. D. *et al.* Dietary and lifestyle guidelines for the prevention of Alzheimer's disease. *Neurobiol. Aging* **35**, S74–S78 (2014).
 94. Sorrentino, P., Iuliano, A., Polverino, A., Jacini, F. & Sorrentino, G. The dark sides of amyloid in Alzheimer's disease pathogenesis. *FEBS Lett.* **588**, 641–652 (2014).
 95. Harrison, J. R. & Owen, M. J. Alzheimer's disease: the amyloid hypothesis on trial. *Br. J. Psychiatry* **208**, 1–3 (2016).
 96. Kepp, K. P. Ten Challenges of the Amyloid Hypothesis of Alzheimer's Disease. *J. Alzheimer's Dis.* **55**, 447–457 (2017).
 97. Robakis, N. K. Mechanisms of AD neurodegeneration may be independent of Abeta and its derivatives. *Neurobiol. Aging* **32**, 372–379 (2011).
 98. Sun, L., Zhou, R., Yang, G. & Shi, Y. Analysis of 138 pathogenic mutations in presenilin-1 on the in vitro production of A β 42 and A β 40 peptides by γ -secretase. *Proc. Natl. Acad. Sci.* **114**, E476–E485 (2016).
 99. Tiwari, M. K. & Kepp, K. P. β -Amyloid pathogenesis: Chemical properties versus cellular levels. *Alzheimer's Dement.* **12**, 184–194 (2016).
 100. Georgakopoulos, A. *et al.* Metalloproteinase/Presenilin1 processing of ephrinB regulates EphB-induced Src phosphorylation and signaling. *EMBO J.* **25**, 1242–1252 (2006).
 101. Song, W. *et al.* Proteolytic release and nuclear translocation of Notch-1 are induced by presenilin-1 and impaired by pathogenic presenilin-1 mutations. *Proc. Natl. Acad. Sci.* **96**, 6959–6963 (1999).
 102. Cacquevel, M., Aeschbach, L., Houacine, J. & Fraering, P. C. Alzheimer's disease-linked mutations in presenilin-1 result in a drastic loss of activity in purified γ -secretase complexes. *PLoS One* **7**, 1–13 (2012).

103. Woodruff, G. *et al.* The Presenilin-1 δ E9 Mutation Results in Reduced γ -Secretase Activity, but Not Total Loss of PS1 Function, in Isogenic Human Stem Cells. *Cell Rep.* **5**, 974–985 (2013).
104. Shioi, J. *et al.* FAD mutants unable to increase neurotoxic A β 42 suggest that mutation effects on neurodegeneration may be independent of effects on Abeta. *J. Neurochem.* **101**, 674–681 (2007).
105. Shen, J. & Kelleher, R. J. The presenilin hypothesis of Alzheimer's disease: evidence for a loss-of-function pathogenic mechanism. *Proc. Natl. Acad. Sci. U. S. A.* **104**, 403–409 (2007).
106. Mehra, R. & Kepp, K. P. Understanding familial Alzheimer's disease: The fit-stay-trim mechanism of γ -secretase. *Wiley Interdiscip. Rev. Comput. Mol. Sci.* **12**, e1556 (2022).
107. Somavarapu, A. K. & Kepp, K. P. Membrane Dynamics of γ -Secretase Provides a Molecular Basis for β -Amyloid Binding and Processing. *ACS Chem. Neurosci.* **8**, 2424–2436 (2017).
108. Somavarapu, A. K. & Kepp, K. P. Loss of stability and hydrophobicity of presenilin 1 mutations causing Alzheimer's Disease. *J. Neurochem.* **137**, 101–111 (2016).
109. Herrup, K. The case for rejecting the amyloid cascade hypothesis. *Nat. Neurosci.* **18**, 794–799 (2015).
110. Francis, R. *et al.* aph-1 and pen-2 are required for Notch pathway signaling, γ -secretase cleavage of β APP, and presenilin protein accumulation. *Dev. Cell* **3**, 85–97 (2002).
111. Bolduc, D. M., Montagna, D. R., Gu, Y., Selkoe, D. J. & Wolfe, M. S. Nicastrin functions to sterically hinder γ -secretase–substrate interactions driven by substrate transmembrane domain. *Proc. Natl. Acad. Sci.* **113**, E509–E518 (2016).
112. Qiu, W. Q. *et al.* Insulin-degrading enzyme regulates extracellular levels of amyloid beta-protein by degradation. *J. Biol. Chem.* **273**, 32730–32738 (1998).
113. Bulloj, A., Leal, M. C., Xu, H., Castaño, E. M. & Morelli, L. Insulin-degrading enzyme sorting in exosomes: a secretory pathway for a key brain amyloid- β degrading protease. *J. Alzheimer's Dis.* **19**, 79–95 (2010).
114. Farris, W. *et al.* Insulin-degrading enzyme regulates the levels of insulin, amyloid β -protein, and the β -amyloid precursor protein intracellular domain in vivo. *Proc. Natl.*

- Acad. Sci.* **100**, 4162–4167 (2003).
115. Malgieri, G. & Grasso, G. The clearance of misfolded proteins in neurodegenerative diseases by zinc metalloproteases: An inorganic perspective. *Coord. Chem. Rev.* **260**, 139–155 (2014).
 116. Miners, J. S., Barua, N., Kehoe, P. G., Gill, S. & Love, S. Abeta-degrading enzymes: potential for treatment of Alzheimer disease. *J. Neuropathol. Exp. Neurol.* **70**, 944–959 (2011).
 117. Carson, J. A. & Turner, A. J. β -Amyloid catabolism: roles for neprilysin (NEP) and other metalloproteases? *J. Neurochem.* **81**, 1–8 (2002).
 118. Drachman, D. A. The amyloid hypothesis, time to move on: Amyloid is the downstream result, not cause, of Alzheimer's disease. *Alzheimer's Dement.* **10**, 372–380 (2014).
 119. Mullane, K. & Williams, M. Alzheimer's disease (AD) therapeutics – 1: Repeated clinical failures continue to question the amyloid hypothesis of AD and the current understanding of AD causality. *Biochem. Pharmacol.* **158**, 359–375 (2018).
 120. Salloway, S. *et al.* Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease. *JAMA Neurol.* **79**, 13–21 (2022).
 121. Giuffrida, M. L. *et al.* β -amyloid monomers are neuroprotective. *J. Neurosci.* **29**, 10582–10587 (2009).
 122. Brookmeyer, R. & Abdalla, N. Estimation of lifetime risks of Alzheimer's disease dementia using biomarkers for preclinical disease. *Alzheimer's & Dement.* **14**, 981–988 (2018).
 123. Jack, C. R. J. *et al.* Prevalence of Biologically vs Clinically Defined Alzheimer Spectrum Entities Using the National Institute on Aging-Alzheimer's Association Research Framework. *JAMA Neurol.* **76**, 1174–1183 (2019).
 124. Sturchio, A. *et al.* High cerebrospinal amyloid- β 42 is associated with normal cognition in individuals with brain amyloidosis. *eClinicalMedicine* **38**, 100988 (2021).
 125. Sturchio, A. *et al.* High Soluble Amyloid- β 42 Predicts Normal Cognition in Amyloid-Positive Individuals with Alzheimer's Disease-Causing Mutations. *J. Alzheimer's Dis.* **90**, 333–348 (2022).